Table 2

Adverse events: weeks 0 through 24

Number of patients* withCZP (N=27)
n (%)
Placebo (N=10)
n (%)
Any TEAE16 (59.3)4 (40.0)
Related TEAEs3 (11.1)0 (0)
Withdrawal from treatment due to TEAE0 (0)1 (10.0)
 Serious TEAEs0 (0)0 (0.0)
 Mild TEAEs7 (25.9)3 (30.0)
 Moderate TEAEs9 (33.3)1 (10)
 Severe TEAEs0 (0.0)0 (0)
 Death due to TEAE0 (0.0)0 (0)
  • *Patients are classified according to initial treatment assignment.

  • CZP, certolizumab pegol; TEAE, treatment-emergent adverse events.